Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Moreover, APRIL-transfected NIH-3T3 cells show an increased rate of tumor growth in nude mice compared with the parental cell line.
|
9743536 |
1998 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Tumor growth-promoting as well as apoptosis-inducing effects of APRIL have been described.
|
11550092 |
2001 |
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The present amplification via primer ligation at the mutation (APRIL-ATM) has potential applications in the detection of mutagen-generated genetic alterations, early detection of tumor marker mutations in bodily discharges and the diagnosis of minimal residual disease.
|
12202623 |
2002 |
Autoimmune Diseases
|
0.060 |
Biomarker
|
group |
BEFREE |
These findings raise the possibility that active BLyS/APRIL heterotrimers may play a role in rheumatic and other autoimmune diseases and that other members of the TNF ligand superfamily may also form active soluble heterotrimers.
|
12370363 |
2002 |
Tumor Progression
|
0.020 |
AlteredExpression
|
phenotype |
BEFREE |
Because these molecules are key regulators of B-cell homeostasis and tumor progression, leukemic cell autocrine expression of BLyS and APRIL may be playing an important role in the pathogenesis of this disease.
|
12351410 |
2002 |
Rheumatism
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
In this study, we show that APRIL and BLyS can form active heterotrimeric molecules when coexpressed and that circulating heterotrimers are present in serum samples from patients with systemic immune-based rheumatic diseases.
|
12370363 |
2002 |
Neoplasm, Residual
|
0.010 |
GeneticVariation
|
phenotype |
BEFREE |
The present amplification via primer ligation at the mutation (APRIL-ATM) has potential applications in the detection of mutagen-generated genetic alterations, early detection of tumor marker mutations in bodily discharges and the diagnosis of minimal residual disease.
|
12202623 |
2002 |
Lupus Erythematosus, Systemic
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A novel polymorphism of the human APRIL gene is associated with systemic lupus erythematosus.
|
12730512 |
2003 |
Lupus Erythematosus, Systemic
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Inverse association between circulating APRIL levels and serological and clinical disease activity in patients with systemic lupus erythematosus.
|
15308519 |
2004 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We detected significantly increased APRIL levels in sera of B cell chronic lymphoid leukemia (B-CLL) patients, indicating that APRIL promotes onset of B-1-associated neoplasms and that APRIL antagonism may provide a therapeutic strategy to treat B-CLL patients.
|
15488762 |
2004 |
Neoplasms
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
APRIL and BAFF are involved in a variety of tumor and autoimmune diseases, including B-cell malignancies.
|
15070697 |
2004 |
Autoimmune Diseases
|
0.060 |
PosttranslationalModification
|
group |
BEFREE |
APRIL and BAFF are involved in a variety of tumor and autoimmune diseases, including B-cell malignancies.
|
15070697 |
2004 |
Autoimmune Diseases
|
0.060 |
Biomarker
|
group |
BEFREE |
APRIL may serve as a down modulator of serological and/or clinical autoimmunity in patients with SLE.
|
15308519 |
2004 |
Chronic Lymphocytic Leukemia
|
0.060 |
Biomarker
|
disease |
BEFREE |
We detected significantly increased APRIL levels in sera of B cell chronic lymphoid leukemia (B-CLL) patients, indicating that APRIL promotes onset of B-1-associated neoplasms and that APRIL antagonism may provide a therapeutic strategy to treat B-CLL patients.
|
15488762 |
2004 |
Chronic Lymphocytic Leukemia
|
0.060 |
Biomarker
|
disease |
BEFREE |
Conversely, adding soluble BCMA-Fc or anti-BAFF and anti-APRIL antibodies enhanced B-CLL apoptosis.
|
14504101 |
2004 |
B-CELL MALIGNANCY, LOW-GRADE
|
0.020 |
Biomarker
|
disease |
BEFREE |
Conversely, adding soluble BCMA-Fc or anti-BAFF and anti-APRIL antibodies enhanced B-CLL apoptosis.
|
14504101 |
2004 |
Glioblastoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Abnormal production of the TNF-homologue APRIL increases the proliferation of human malignant glioblastoma cell lines via a specific receptor.
|
14691452 |
2004 |
Adult Glioblastoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Abnormal production of the TNF-homologue APRIL increases the proliferation of human malignant glioblastoma cell lines via a specific receptor.
|
14691452 |
2004 |
Childhood Glioblastoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Abnormal production of the TNF-homologue APRIL increases the proliferation of human malignant glioblastoma cell lines via a specific receptor.
|
14691452 |
2004 |
Glioblastoma Multiforme
|
0.010 |
Biomarker
|
disease |
BEFREE |
Abnormal production of the TNF-homologue APRIL increases the proliferation of human malignant glioblastoma cell lines via a specific receptor.
|
14691452 |
2004 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Finally, whereas interaction of APRIL with HSPG does not influence APRIL-induced proliferation of T cells, it is crucial for its tumor growth-promoting activities.
|
15846369 |
2005 |
Rheumatoid Arthritis
|
0.070 |
Biomarker
|
disease |
BEFREE |
BLyS and APRIL in rheumatoid arthritis.
|
16239971 |
2005 |
Chronic Lymphocytic Leukemia
|
0.060 |
AlteredExpression
|
disease |
BEFREE |
The CXCR5/CXCL13 pair by means of activation of APRIL (A proliferation-inducing ligand) induced resistance to apoptosis in T-ALL CD8(+)CD34(+) T cells in livin-dependent manner.
|
15580304 |
2005 |
Multiple Sclerosis
|
0.030 |
Biomarker
|
disease |
BEFREE |
Levels of soluble APRIL in plasma were higher in patients with chronic progressive MS than in patients with relapsing-remitting MS, albeit not significantly.
|
16087247 |
2005 |
Lupus Erythematosus, Systemic
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The APRIL codon 67 was significantly associated with SLE risk under the dominant model adjusted by ethnicity (odds ratio, 95% confidence interval and P-values were 1.45 and 1.02-2.06 and 0.036, respectively).
|
17569747 |
2007 |